Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Bladder Dysfunction Reports

02.04.2024 | REVIEW

Bladder Cancer Diagnosis and Treatment for Patients with Neurogenic Bladder: Does the Literature Support a Different Approach?

verfasst von: M. P. Bigarella, K. A. Richards

Erschienen in: Current Bladder Dysfunction Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this review, the current literature available to patients and providers on the diagnosis and management of bladder cancer in patients with neurogenic bladder will be discussed. Topics include bladder cancer epidemiology in the neurogenic population and unique features of this tumor in this subset of patients, current screening recommendations, and differences in the treatment for this patient population, outlining specific changes in the surgical approach.

Recent Findings

Neurogenic lower urinary tract dysfunction (NLUTD) patients are living longer due to better care, and cancer is becoming more frequent. This is partly due to the aging of this population, as well as intrinsic factors related to the underlying condition or urinary diversion, which poses a greater risk of developing genitourinary malignancies. There are multiple studies published that have investigated this specific patient population, most derived from large cohorts of patients with spinal cord injury.

Summary

Although there is more evidence on screening for bladder cancer, specific screening protocols for different underlying conditions and urinary diversion are lacking. Few studies have looked prospectively into the management of bladder cancer in this subset of patients, and good quality evidence for tailoring the care of this population is lacking. Nonetheless, surgical complications are expected to be greater in this scenario.
Literatur
1.
Hartkopp A, et al. Survival and cause of death after traumatic spinal cord injury. A long-term epidemiological survey from Denmark. Spinal Cord. 1997;35(2):76–85.PubMedCrossRef
2.
Brandes SB, et al. Renal cell carcinoma in patients with prior spinal cord injury. J Spinal Cord Med. 2001;24(4):251–6.PubMedCrossRef
3.
• Ismail S, et al. Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourol Urodyn. 2018;37(4):1386–95. (Systematic review on prevalence and mortality of bladder cancer in NGB population.)PubMedCrossRef
4.
Nahm LS, et al. Bladder cancer mortality after spinal cord injury over 4 decades. J Urol. 2015;193(6):1923–8.PubMedCrossRef
5.
6.
•• Liu B, Welk B. Urological malignancies in neurogenic patients. Curr Opin Urol. 2020;30(4):501–6. (Review article, overview of urologic malignancies in patients with NGB, mostly focused on prostate and bladder cancer. The review showed a lower incidence of bladder cancer in the NLUTD population than previously found.)PubMedCrossRef
7.
Welk B, et al. Bladder cancer in individuals with spinal cord injuries. Spinal Cord. 2013;51(7):516–21.PubMedCrossRef
8.
• Prattley S, New F, Davies M. Malignancies of suprapubic catheter (SPC) tracts in spinal cord injury patients: a case series and review of literature. Spinal Cord Ser Cases. 2019;5:34. https://​doi.​org/​10.​1038/​s41394-019-0177-9. (Authors presented the first case series of malignancy of the SPC tract in SCI patients.)
9.
•• Bothig R, et al. Clinical characteristics of bladder cancer in patients with spinal cord injury: the experience from a single centre. Int Urol Nephrol. 2017;49(6):983–94. (Single-centre retrospective evaluation of patient data with spinal cord injuries and proven urinary bladder cancer and summary of the literature. The authors found that younger age at onset and the frequency of invasive tumours at diagnosis indicate that spinal cord injury influences bladder cancer risk and prognosis.)PubMedCrossRef
10.
Gui-Zhong L, Li-Bo M. Bladder cancer in individuals with spinal cord injuries: a meta-analysis. Spinal Cord. 2017;55(4):341–5.PubMedCrossRef
11.
Rove KO, et al. Systematic review of bladder cancer outcomes in patients with spina bifida. J Pediatr Urol. 2017;13(5):456 e1-456 e9.PubMedCrossRef
12.
De Ridder D, et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol. 1998;159(6):1881–4.PubMedCrossRef
13.
Lebrun C, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler. 2008;14(3):399–405.PubMedCrossRef
14.
15.
• Marrie RA, et al. Cancer incidence and mortality rates in multiple sclerosis: a matched cohort study. Neurology. 2021;96(4):e501–12. (The authors found that the incidence of breast and colorectal cancers does not differ between persons with and without MS; however, the incidence of bladder cancer is increased. Overview of bladder cancer incidence and mortality among patients with Multiple Sclerosis.)PubMedCrossRef
16.
Grytten N, et al. Incidence of cancer in multiple sclerosis before and after the treatment era- a registry- based cohort study. Mult Scler Relat Disord. 2021;55:103209.PubMedCrossRef
17.
Ho CH, et al. Chronic indwelling urinary catheter increase the risk of bladder cancer, even in patients without spinal cord injury. Medicine (Baltimore). 2015;94(43):e1736.PubMedCrossRef
18.
Cameron AP, Rodriguez GM, Schomer KG. Systematic review of urological followup after spinal cord injury. J Urol. 2012;187(2):391–7.PubMedCrossRef
19.
20.
Stonehill WH, et al. Risk factors for bladder tumors in spinal cord injury patients. J Urol. 1996;155(4):1248–50.PubMedCrossRef
21.
Pannek J. Transitional cell carcinoma in patients with spinal cord injury: a high risk malignancy? Urology. 2002;59(2):240–4.PubMedCrossRef
22.
Biardeau X, et al. Risk of malignancy after augmentation cystoplasty: a systematic review. Neurourol Urodyn. 2016;35(6):675–82.PubMedCrossRef
23.
Hoen L, et al. Long-term effectiveness and complication rates of bladder augmentation in patients with neurogenic bladder dysfunction: a systematic review. Neurourol Urodyn. 2017;36(7):1685–702.PubMedCrossRef
24.
Groah SL, et al. Excess risk of bladder cancer in spinal cord injury: evidence for an association between indwelling catheter use and bladder cancer. Arch Phys Med Rehabil. 2002;83(3):346–51.PubMedCrossRef
25.
Esrig D, McEvoy K, Bennett CJ. Bladder cancer in the spinal cord-injured patient with long-term catheterization: a casual relationship? Semin Urol. 1992;10(2):102–8.PubMed
26.
Hamid R, et al. Epidemiology and pathophysiology of neurogenic bladder after spinal cord injury. World J Urol. 2018;36(10):1517–27.PubMedCrossRef
27.
•• Bothig R, et al. Traumatic spinal cord injury confers bladder cancer risk to patients managed without permanent urinary catheterization: lessons from a comparison of clinical data with the national database. World J Urol. 2020;38(11):2827–34. (Single-centre retrospective evaluation of consecutive in- and out-patient data with spinal cord injury, focusing on bladder cancer risks in the neurogenic bladder population. The author found that in patients with SCI bladder management even without permanent catheterization represents a considerable risk for the development of bladder tumors.)PubMedCrossRef
28.
Ginsberg DA, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: treatment and follow-up. J Urol. 2021;206(5):1106–13.PubMedCrossRef
29.
Ginsberg DA, et al. The AUA/SUFU guideline on adult neurogenic lower urinary tract dysfunction: diagnosis and evaluation. J Urol. 2021;206(5):1097–105.PubMedCrossRef
30.
El Masri y WS, et al. To cystoscope or not to cystoscope patients with traumatic spinal cord injuries managed with indwelling urethral or suprapubic catheters? That is the question! Spinal Cord. 2014;52(1):49–53.PubMedCrossRef
31.
Hamid R, et al. Screening cystoscopy and biopsy in patients with neuropathic bladder and chronic suprapubic indwelling catheters: is it valid? J Urol. 2003;170(2 Pt 1):425–7.PubMedCrossRef
32.
Hamid R, et al. Routine surveillance cystoscopy for patients with augmentation and substitution cystoplasty for benign urological conditions: is it necessary? BJU Int. 2009;104(3):392–5.PubMedCrossRef
33.
Fitzpatrick R, Baverstock R. Muscle invasive bladder cancer presenting as recurrent autonomic dysreflexia - a wolf in wolf’s clothing. J Spinal Cord Med. 2020;43(4):540–3.PubMedCrossRef
34.
Davis M. When guidelines conflict: patient safety, quality of life, and CAUTI reduction in patients with spinal cord injury. Spinal Cord Ser Cases. 2019;5:56.PubMedPubMedCentralCrossRef
35.
Lewis J, et al. A framework for transitioning patients from pediatric to adult health settings for patients with neurogenic bladder. Neurourol Urodyn. 2017;36(4):973–8.PubMedCrossRef
36.
Flaig TW, et al. NCCN guidelines(R) insights: bladder cancer, version 2.2022. J Natl Compr Canc Netw. 2022;20(8):866–78.PubMedCrossRef
37.
Necchi A, et al. Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies. Eur Urol. 2020;77(4):439–46.PubMedCrossRef
38.
Song Y, Xu T. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. World J Urol. 2023;41(6):1697–8.PubMedCrossRef
39.
Delnay KM, et al. Bladder histological changes associated with chronic indwelling urinary catheter. J Urol. 1999;161(4):1106–8 (discussion 1108-9).PubMedCrossRef
40.
• Sampogna G, et al. Experience of a tertiary referral center in managing bladder cancer in conjunction with neurogenic bladder. Spinal Cord Ser Cases. 2020;6(1):61. (Single-center retrospective analysis with pre, intra and post operative data for NB with BCa. The authors found that BCa in individuals with NB is associated with a diagnosis at an advanced stage and a high rate of surgical complications.)PubMedPubMedCentralCrossRef
41.
McMichan JC, Michel L, Westbrook PR. Pulmonary dysfunction following traumatic quadriplegia. Recognition, prevention, and treatment. JAMA. 1980;243(6):528–31.PubMedCrossRef
42.
43.
Shimko MS, et al. Long-term complications of conduit urinary diversion. J Urol. 2011;185(2):562–7.PubMedCrossRef
44.
•• Bothig R, et al. Special surgical aspects of radical cystectomy in spinal cord injury patients with bladder cancer. World J Urol. 2022;40(8):1961–70. (Single-center retrospective analysis with pre, intra and post operative data for NB with BCa. Very useful management considerations for pre, intra and post operative steps to avoid complication, based on authors` expertise.)PubMedCrossRef
45.
Cheng JN, et al. Cystectomy in patients with spinal cord injury: indications and long-term outcomes. J Urol. 2010;184(1):92–8.PubMedCrossRef
46.
Guillot-Tantay C, et al. Complications of non-continent cutaneous urinary diversion in adults with spinal cord injury: a retrospective study. Spinal Cord. 2018;56(9):856–62.PubMedCrossRef
47.
Metadaten
Titel
Bladder Cancer Diagnosis and Treatment for Patients with Neurogenic Bladder: Does the Literature Support a Different Approach?
verfasst von
M. P. Bigarella
K. A. Richards
Publikationsdatum
02.04.2024
Verlag
Springer US
Erschienen in
Current Bladder Dysfunction Reports
Print ISSN: 1931-7212
Elektronische ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-024-00747-5

Neu im Fachgebiet Urologie

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise